RS68111B1 - Derivati 3-(2-(heteroaril)-piridin-4-il)-5-(trifluormetil)-1,2,4-oksadiazola kao inhibitori hdac6 - Google Patents

Derivati 3-(2-(heteroaril)-piridin-4-il)-5-(trifluormetil)-1,2,4-oksadiazola kao inhibitori hdac6

Info

Publication number
RS68111B1
RS68111B1 RS20260600A RSP20260600A RS68111B1 RS 68111 B1 RS68111 B1 RS 68111B1 RS 20260600 A RS20260600 A RS 20260600A RS P20260600 A RSP20260600 A RS P20260600A RS 68111 B1 RS68111 B1 RS 68111B1
Authority
RS
Serbia
Prior art keywords
pyridin
trifluoromethyl
compound
pyrrolo
oxadiazol
Prior art date
Application number
RS20260600A
Other languages
English (en)
Serbian (sr)
Inventor
González Elena Carceller
Muñoz Alberto Ortega
Solana Jorge Salas
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of RS68111B1 publication Critical patent/RS68111B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20260600A 2019-06-06 2020-06-05 Derivati 3-(2-(heteroaril)-piridin-4-il)-5-(trifluormetil)-1,2,4-oksadiazola kao inhibitori hdac6 RS68111B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19382475 2019-06-06
EP19383221 2019-12-31
EP20732166.2A EP3980416B1 (en) 2019-06-06 2020-06-05 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors
PCT/EP2020/065658 WO2020245381A1 (en) 2019-06-06 2020-06-05 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors

Publications (1)

Publication Number Publication Date
RS68111B1 true RS68111B1 (sr) 2026-06-30

Family

ID=71083614

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20260600A RS68111B1 (sr) 2019-06-06 2020-06-05 Derivati 3-(2-(heteroaril)-piridin-4-il)-5-(trifluormetil)-1,2,4-oksadiazola kao inhibitori hdac6

Country Status (13)

Country Link
US (1) US12522598B2 (enExample)
EP (2) EP4789722A2 (enExample)
JP (1) JP7523146B2 (enExample)
CN (1) CN114206868B (enExample)
CA (1) CA3142435A1 (enExample)
DK (1) DK3980416T3 (enExample)
FI (1) FI3980416T3 (enExample)
HR (1) HRP20260656T1 (enExample)
LT (1) LT3980416T (enExample)
MX (1) MX2021014918A (enExample)
RS (1) RS68111B1 (enExample)
SI (1) SI3980416T1 (enExample)
WO (1) WO2020245381A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
MX2020005841A (es) 2017-12-05 2020-09-07 Oryzon Genomics Sa Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101618B2 (en) 2005-04-06 2012-01-24 Msd K.K. 1,4-substituted piperazine derivatives
US20100136024A1 (en) 2008-11-14 2010-06-03 Bartels Stephen P Selective Inhibition of Histone Deacetylase 6 for Ocular Neuroprotection or for Treatment or Control of Glaucoma
NZ610225A (en) 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
CA2856334A1 (en) 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
EP3187497A4 (en) 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10357484B2 (en) 2015-07-17 2019-07-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN108026088B (zh) 2015-07-17 2021-02-12 武田药品工业株式会社 用作hdac抑制剂的噁二唑衍生物
WO2017033946A1 (ja) 2015-08-25 2017-03-02 武田薬品工業株式会社 複素環化合物
JP6970680B2 (ja) 2016-03-15 2021-11-24 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤
WO2017222952A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222950A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
EP3475275B1 (en) * 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018118781A1 (en) 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles
MX2020005841A (es) 2017-12-05 2020-09-07 Oryzon Genomics Sa Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.

Also Published As

Publication number Publication date
JP2022535290A (ja) 2022-08-05
SI3980416T1 (sl) 2026-07-31
HRP20260656T1 (hr) 2026-07-03
LT3980416T (lt) 2026-06-10
EP3980416B1 (en) 2026-03-11
DK3980416T3 (da) 2026-05-26
CA3142435A1 (en) 2020-12-10
US20220298156A1 (en) 2022-09-22
EP3980416A1 (en) 2022-04-13
FI3980416T3 (fi) 2026-05-21
JP7523146B2 (ja) 2024-07-26
WO2020245381A1 (en) 2020-12-10
US12522598B2 (en) 2026-01-13
EP4789722A2 (en) 2026-08-12
CN114206868B (zh) 2025-02-25
CN114206868A (zh) 2022-03-18
MX2021014918A (es) 2022-06-27